Redhill Biopharma Ltd. (RDHL) SEC Filings — 2025
38 SEC filings for Redhill Biopharma Ltd. (RDHL) in 2025.
Filings
- RedHill Biopharma Files 6-K with Pro Forma Financials — 6-K · Dec 31, 2025
- RedHill Biopharma Secures $10M Equity Line — 6-K · Dec 23, 2025
- Redhill Biopharma Ltd. 6-K Filing — 6-K · Dec 15, 2025
- Redhill Biopharma Ltd. 6-K Filing — 6-K · Dec 1, 2025
- Redhill Biopharma Ltd. 6-K Filing — 6-K · Nov 26, 2025
- Redhill Biopharma Ltd. 6-K Filing — 6-K · Nov 4, 2025
- RedHill Biopharma Faces Nasdaq Delisting Risk — 6-K · Oct 22, 2025
- RedHill Biopharma Amends Share Purchase Agreement — 6-K · Oct 21, 2025
- RedHill Biopharma Files 6-K, Incorporates Prior Filings — 6-K · Oct 20, 2025
- RedHill Biopharma Secures $1.8M+ Middle East Deal for Talicia® — 6-K · Oct 6, 2025
- RedHill Biopharma Wins $10M Court Appeal Against Kukbo — 6-K · Sep 29, 2025
- RedHill Biopharma Files 6-K, Details Hyloris Deal & Warrants — 6-K · Sep 5, 2025
- RedHill Biopharma Wins $1.8M Legal Costs, Totaling $10.05M — 6-K · Aug 20, 2025
- RedHill Biopharma Receives $1.1M in Talicia Licensing Payments — 6-K · Aug 18, 2025
- RedHill Biopharma Files 6-K, Incorporates by Reference — 6-K · Aug 14, 2025
- RedHill Biopharma Gets FDA Nod for Crohn's Drug — 6-K · Jul 21, 2025
- RedHill Biopharma Starts Expanded Phase 2 Prostate Cancer Study — 6-K · Jul 1, 2025
- RedHill Biopharma Secures Up To $10M Equity Line — 6-K · Jun 25, 2025
- RedHill Biopharma Shareholders Approve All Resolutions — 6-K · May 27, 2025
- RedHill Biopharma Updates on Share Purchase Warrants — 6-K · May 19, 2025
- RedHill Biopharma Wins $8.25M Judgment, Freezes Kukbo Assets — 6-K · May 13, 2025
- RedHill Biopharma Adjourns Shareholder Meeting Due to Lack of Quorum — 6-K · May 5, 2025
- RedHill Biopharma Supports H. Pylori Education Launch — 6-K · May 2, 2025
- RedHill Biopharma's COVID-19 Drug RHB-107 Gets Key China Patent Allowance — 6-K · Apr 28, 2025
- RedHill Biopharma Faces Nasdaq Delisting Risk — 6-K · Apr 17, 2025
- RedHill Biopharma Opaganib Data Published — 6-K · Apr 16, 2025
- RedHill Biopharma Reports 2024 Financials & Highlights — 6-K · Apr 10, 2025
- RedHill Biopharma Files 2024 Annual Report — 20-F · Apr 10, 2025
- RedHill Biopharma Files 6-K Report — 6-K · Apr 8, 2025
- RedHill Biopharma Schedules May 5th Shareholder Meeting — 6-K · Apr 1, 2025
- RedHill Biopharma Schedules Annual General Meeting for May 5 — 6-K · Mar 26, 2025
- RedHill Biopharma Seeks UK Approval for Talicia® — 6-K · Mar 18, 2025
- RedHill Biopharma Advances Crohn's Disease Program on Positive Phase 3 Data — 6-K · Mar 12, 2025
- RedHill Biopharma Presents Business Update at Sachs Forum — 6-K · Feb 27, 2025
- RedHill Biopharma Licenses RHB-102 to Hyloris for up to $60M — 6-K · Feb 25, 2025
- RedHill Biopharma Starts Phase 2 Prostate Cancer Study — 6-K · Feb 4, 2025
- RedHill Biopharma Enters At-the-Market Offering Agreement — 6-K · Feb 3, 2025
- RedHill's Talicia Gains Humana Coverage, Expands Reach — 6-K · Jan 21, 2025